iMTA performed a costing study for intrathecal baclofen therapy against spasms, also occurring in multiple sclerosis. The pump was fitted in a home based situation to avoid that patients have to return to the hospital.
Cost Effectiveness in Neurology
Multiple Sclerosis treatment is improving, but do we capture these effects?
Key achievements in the field of Multiple Sclerosis
Preference measurement DCE / TTO
iMTA developed the condition specific MSIS-PBM, a preference based instrument based on the Multiple Sclerosis Impact Scale 29. Using the Time Trade-off method in about 400 group interviews in The Netherlands, a selection of items (selected using Rasch-analysis and expert opinion) of the MSIS-29 was weighted. The resulting instrument is more sensitive than EQ5D for minor impairments and better discriminates between patients with EDSS score 3,4 and 5 than EQ5D. Utilities can be calculated from the MSIS-29 directly.